| 2106 | Parkinson disease |
| 1952 | Humans |
| 1358 | Human |
| 1214 | Male |
| 1073 | Female |
| 944 | Middle Aged |
| 914 | Aged |
| 770 | Nervous system diseases |
| 628 | Treatment |
| 621 | Parkinson Disease (physiopathology) |
| 546 | Animals |
| 485 | Adult |
| 472 | Parkinson Disease (drug therapy) |
| 382 | Parkinson Disease (therapy) |
| 324 | Parkinson Disease (complications) |
| 291 | Chemotherapy |
| 261 | Antiparkinson agent |
| 259 | Parkinson Disease (pathology) |
| 248 | Parkinson's disease |
| 248 | Animal |
| 244 | Parkinson Disease (metabolism) |
| 234 | Review |
| 231 | Subthalamic nucleus |
| 230 | Aged, 80 and over |
| 228 | Dopamine |
| 227 | Levodopa |
| 225 | Antiparkinson Agents (therapeutic use) |
| 208 | Parkinson Disease (genetics) |
| 205 | Levodopa (therapeutic use) |
| 195 | Parkinson Disease (psychology) |
| 184 | Disease Models, Animal |
| 180 | Treatment Outcome |
| 168 | Rats |
| 166 | Rat |
| 165 | Elderly |
| 161 | Toxicity |
| 160 | Degenerative disease |
| 153 | Parkinson Disease (diagnosis) |
| 150 | France |
| 148 | Pathophysiology |
| 142 | Exploration |
| 142 | Dopamine (metabolism) |
| 137 | Neuropsychological Tests |
| 137 | Alzheimer disease |
| 132 | Antiparkinson Agents (adverse effects) |
| 129 | Dopaminergic neuron |
| 127 | Comparative study |
| 125 | Parkinsonism |
| 123 | Severity of Illness Index |
| 123 | Levodopa (adverse effects) |
| 117 | Basal ganglion |
| 117 | Animal model |
| 115 | Subthalamic Nucleus (physiology) |
| 115 | Diagnosis |
| 111 | Mice |
| 108 | Corpus striatum |
| 107 | Deep Brain Stimulation (methods) |
| 106 | Pathogenesis |
| 106 | Parkinson Disease (epidemiology) |
| 106 | Locus niger |
| 106 | Dyskinesia |
| 105 | Mutation |
| 101 | Case-Control Studies |
| 101 | Case study |
| 99 | Brain (vertebrata) |
| 97 | Complication |
| 96 | Time Factors |
| 96 | Deep brain stimulation |
| 93 | Follow-Up Studies |
| 92 | Dopamine agonist |
| 90 | Wolff Parkinson White syndrome |
| 89 | Surgery |
| 89 | Subthalamic Nucleus (physiopathology) |
| 89 | Parkinson Disease (surgery) |
| 86 | Neurons (metabolism) |
| 85 | Adolescent |
| 84 | Mouse |
| 84 | Cardiovascular disease |
| 83 | Dementia |
| 82 | Electrodes, Implanted |
| 82 | Deep Brain Stimulation |
| 81 | Depression |
| 80 | Instrumental stimulation |
| 78 | Parkinson Disease, Secondary (chemically induced) |
| 78 | Magnetic Resonance Imaging |
| 78 | Degeneration |
| 78 | Agonist |
| 76 | Cognitive disorder |
| 75 | Child |
| 74 | Risk Factors |
| 74 | Epidemiology |
| 73 | Prospective Studies |
| 73 | Prognosis |
| 73 | Cognition |
| 72 | Substantia Nigra (pathology) |
| 72 | Neuron |
| 72 | Immunohistochemistry |
| 72 | Electrical stimulus |
| 71 | Electrophysiology |
| 71 | Electric Stimulation Therapy |
| 71 | Brain (pathology) |
| 70 | Antiparkinson Agents (administration & dosage) |
| 68 | Neurons (pathology) |
| 68 | Monkey |
| 68 | Medicine |
| 68 | Encephalon |
| 68 | Double-Blind Method |
| 67 | Parkinson Disease (etiology) |
| 67 | Parkinson Disease (diagnostic imaging) |
| 67 | Neurons (physiology) |
| 67 | Mechanism of action |
| 67 | Corpus Striatum (metabolism) |
| 67 | Cell death |
| 65 | Risk factor |
| 65 | Pallidum |
| 65 | Multiple system atrophy |
| 65 | Dopamine (physiology) |
| 65 | Brain (metabolism) |
| 65 | Arrhythmia |
| 64 | Prevalence |
| 64 | Genetics |
| 63 | Retrospective Studies |
| 63 | Oxidopamine |
| 63 | Neurotoxin |
| 63 | Emission tomography |
| 62 | Substantia Nigra (metabolism) |
| 62 | Analysis of Variance |
| 61 | Rats, Sprague-Dawley |
| 61 | Levodopa (pharmacology) |
| 61 | Dose-Response Relationship, Drug |
| 60 | Levodopa (administration & dosage) |
| 60 | Instrumentation therapy |
| 60 | Disease Progression |
| 60 | Brain (physiopathology) |
| 60 | Apoptosis |
| 59 | Central nervous system |
| 58 | Tremor |
| 58 | Symptomatology |
| 58 | Evolution |
| 58 | Antiparkinson Agents (pharmacology) |
| 55 | Dopamine Agonists (therapeutic use) |
| 54 | Neuroprotective agent |
| 54 | Electrocardiography |
| 53 | Reference Values |
| 53 | Rats, Wistar |
| 53 | In vitro |
| 53 | D2 Dopamine receptor |
| 52 | Tyrosine 3-Monooxygenase (metabolism) |
| 52 | Nuclear magnetic resonance imaging |
| 52 | Chronic |
| 51 | Movement (physiology) |
| 51 | Electromyography |
| 51 | Diagnosis, Differential |
| 50 | Subthalamic Nucleus (surgery) |
| 50 | Posture |
| 50 | Dopamine receptor |
| 49 | Neurons (drug effects) |
| 49 | Mice, Inbred C57BL |
| 49 | Deep Brain Stimulation (adverse effects) |
| 49 | Brain Mapping |
| 48 | Thalamus |
| 48 | Oxidative stress |
| 47 | Surveys and Questionnaires |
| 47 | Psychotropic |
| 47 | Parkinson Disease, Secondary (physiopathology) |
| 47 | Differential diagnostic |
| 46 | Young Adult |
| 46 | Public health |
| 46 | Indication |
| 46 | Genotype |
| 45 | deep brain stimulation |
| 45 | Technique |
| 45 | Huntington disease |
| 45 | High frequency |
| 45 | Gene |
| 45 | Dyskinesia, Drug-Induced (etiology) |
| 45 | Cognition Disorders (etiology) |
| 45 | Basal Ganglia (physiopathology) |
| 44 | Treatment efficiency |
| 44 | France (epidemiology) |
| 44 | Etiology |
| 44 | Dopa |
| 43 | Stimulation |
| 43 | Stereotaxic Techniques |
| 43 | Reproducibility of Results |
| 43 | Psychometrics |
| 43 | Phenotype |
| 43 | Gene expression |
| 43 | Cross-Sectional Studies |
| 42 | Incidence |
| 42 | Age of Onset |
| 41 | Pain |
| 41 | Electrodiagnosis |
| 40 | Supranuclear ophthalmoplegia |
| 40 | Midbrain |
| 40 | Long term |
| 40 | Electroencephalography |
| 40 | Dystonia |
| 40 | Drug Therapy, Combination |
| 40 | Age Factors |
| 39 | dopamine |
| 39 | basal ganglia |
| 39 | Reaction Time (physiology) |
| 39 | Quality of Life |
| 39 | Lesion |
| 39 | Evaluation |
| 39 | Europe |
| 38 | subthalamic nucleus |
| 38 | Sleep disorder |
| 38 | Recommendation |
| 38 | Psychomotor Performance (physiology) |
| 38 | Nigrostriatal pathway |
| 38 | Neurologic Examination |
| 38 | Motor Activity (drug effects) |
| 38 | Macaca fascicularis |
| 38 | Corpus Striatum (pathology) |
| 37 | Substantia Nigra (physiopathology) |
| 37 | Statistics, Nonparametric |
| 37 | Experimental disease |
| 37 | Drug |
| 37 | Corpus Striatum (drug effects) |
| 36 | Senescence |
| 36 | Motor control |
| 36 | Gerontology |
| 36 | Dyskinesia, Drug-Induced (physiopathology) |
| 36 | Behavior |
| 35 | alpha-Synuclein (metabolism) |
| 35 | Positron emission tomography |
| 35 | Motor system disorder |
| 35 | Globus Pallidus (physiopathology) |
| 35 | Genetic Predisposition to Disease |
| 35 | Bilateral |
| 34 | Prevention |
| 34 | Neuroleptic |
| 34 | Corpus Striatum (physiopathology) |
| 33 | Wolff-Parkinson-White Syndrome (physiopathology) |
| 33 | Tomography, Emission-Computed, Single-Photon |
| 33 | Psychiatric Status Rating Scales |
| 33 | Mutation (genetics) |
| 33 | Evaluation scale |
| 33 | Clinical Trials as Topic |
| 32 | Photon |
| 32 | Parkinson’s disease |
| 32 | Motor Activity (physiology) |
| 32 | Magnetic Resonance Imaging (methods) |
| 32 | Heart |
| 32 | Cohort Studies |
| 32 | Cerebral disorder |
| 32 | Age |
| 31 | Reeducation |
| 31 | Oral administration |
| 31 | Neuroprotective Agents (therapeutic use) |
| 31 | Glutamate |
| 31 | Gene therapy |
| 31 | Gait Disorders, Neurologic (etiology) |
| 31 | Electric Stimulation |
| 31 | Brain (drug effects) |
| 30 | Parkinson Disease, Secondary (pathology) |
| 30 | Nerve Degeneration (pathology) |
| 30 | Lewy body |
| 30 | Functional Laterality |
| 30 | Functional Laterality (physiology) |
| 30 | Epilepsy |
| 30 | Electric Stimulation Therapy (methods) |
| 30 | Dopaminergic pathway |
| 30 | Dopamine Agonists (adverse effects) |
| 30 | Apathy |
| 30 | Antagonist |
| 30 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 29 | Wolff-Parkinson-White Syndrome (surgery) |
| 29 | Positron-Emission Tomography |
| 29 | Motor Cortex (physiopathology) |
| 29 | Metabolism |
| 29 | Mental disorder |
| 29 | Disability Evaluation |
| 29 | Clinical management |
| 29 | Body movement |
| 29 | Advanced stage |
| 28 | Ubiquitin-Protein Ligases (genetics) |
| 28 | Ropinirole |
| 28 | Psychosis |
| 28 | Neurology |
| 28 | Mitochondria |
| 28 | Mice, Knockout |
| 28 | Malignant tumor |
| 28 | Iron |
| 28 | Extrapyramidal syndrome |
| 27 | Tyrosine 3-monooxygenase |
| 27 | Quality of life |
| 27 | Pathology |
| 27 | Mesencephalon (pathology) |
| 27 | Enzyme inhibitor |
| 27 | Emotion emotionality |
| 27 | Dyskinesia, Drug-Induced (drug therapy) |
| 27 | Dopamine Agonists (pharmacology) |
| 27 | Dopamine Agents (therapeutic use) |
| 27 | Disease |
| 27 | Combined Modality Therapy |
| 27 | Cognition Disorders (diagnosis) |
| 27 | Bromocriptine |
| 27 | Association |
| 27 | Activities of Daily Living |
| 26 | Subthalamic Nucleus (pathology) |
| 26 | Substantia Nigra (drug effects) |
| 26 | Protein-Serine-Threonine Kinases (genetics) |
| 26 | Predictive Value of Tests |
| 26 | Pharmacokinetics |
| 26 | Parkinson Disease (enzymology) |
| 26 | Neural Pathways (physiopathology) |
| 26 | Nerve Tissue Proteins (genetics) |
| 26 | Models |
| 26 | Models, Neurological |
| 26 | Lewy body dementia |
| 26 | Dopaminergic Neurons (metabolism) |
| 26 | Behavioral disorder |
| 26 | Basal Ganglia (pathology) |
| 25 | alpha-Synuclein (genetics) |
| 25 | Wolff-Parkinson-White Syndrome (diagnosis) |
| 25 | Tomography, Emission-Computed |
| 25 | Reaction Time |
| 25 | Positron |
| 25 | Mesencephalon (metabolism) |
| 25 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
| 25 | Gait disorder |
| 25 | Dysarthria |
| 25 | Cognition (physiology) |
| 25 | Clinical trial |
| 25 | Brain |
| 25 | Basal Ganglia (metabolism) |
| 25 | Amyotrophic lateral sclerosis |
| 24 | Neuroprotective Agents (pharmacology) |
| 24 | Motor cortex |
| 24 | Genetic determinism |
| 24 | Gait (physiology) |
| 24 | Electrodes |
| 24 | Electric Stimulation Therapy (adverse effects) |
| 24 | Dopamine Agonists (administration & dosage) |
| 24 | Cells, Cultured |
| 24 | Catecholamine |
| 24 | Behavior, Animal (drug effects) |
| 23 | substantia nigra |
| 23 | levodopa |
| 23 | Walking |
| 23 | Speech |
| 23 | Serotonin |
| 23 | Sensitivity and Specificity |
| 23 | Pesticides |
| 23 | Pedigree |
| 23 | Parkinson Disease, Secondary (drug therapy) |
| 23 | Parkinson Disease (blood) |
| 23 | Movement Disorders (physiopathology) |
| 23 | Models, Biological |
| 23 | Memory |
| 23 | Memory disorder |
| 23 | Idiopathic |
| 23 | Hallucination |
| 23 | Graft |
| 23 | Frontal Lobe (physiopathology) |
| 23 | Free radical |
| 23 | Executive function |
| 23 | Double blind study |
| 23 | Depression (etiology) |
| 23 | Denervation |
| 23 | Brain (diagnostic imaging) |
| 22 | Tremor (therapy) |
| 22 | Polysomnography |
| 22 | Motricity |
| 22 | MPTP |
| 22 | Inflammation |
| 22 | In vivo |
| 22 | Geriatrics |
| 22 | Gait |
| 22 | Family study |
| 22 | Experimental study |
| 22 | Early |
| 22 | Consensus conference |
| 22 | Comorbidity |
| 22 | Child, Preschool |
| 22 | Cerebral Cortex (physiopathology) |
| 22 | Biological activity |
| 22 | Akinesia |
| 21 | rat |
| 21 | dementia |
| 21 | Multiple sclerosis |
| 21 | Motivation |
| 21 | Locomotion |
| 21 | Image Processing, Computer-Assisted |
| 21 | Gait Disorders, Neurologic (physiopathology) |
| 21 | Drug combination |
| 21 | Dementia (diagnosis) |
| 21 | Cognition Disorders (physiopathology) |
| 21 | Cerebral cortex |
| 21 | Biological receptor |
| 21 | Alzheimer Disease (physiopathology) |
| 21 | Alzheimer Disease (metabolism) |
| 20 | Tyrosine 3-Monooxygenase (analysis) |
| 20 | Transplantation |
| 20 | Thalamic Nuclei (physiopathology) |
| 20 | Schizophrenia |
| 20 | Safety |
| 20 | Rapid eye movement sleep |
| 20 | RNA, Messenger (metabolism) |
| 20 | Progressive |
| 20 | Pilot Projects |
| 20 | Performance evaluation |
| 20 | Parkinsonian Disorders (metabolism) |
| 20 | Parkinson Disease (history) |
| 20 | Movement |
| 20 | Limbic system |
| 20 | Kinetics |
| 20 | Involuntary movement |
| 20 | In Situ Hybridization |
| 20 | Health |
| 20 | Ergot derivatives |
| 20 | Drug Administration Schedule |
| 20 | Dopaminergic Neurons (drug effects) |
| 20 | Bromocriptine (therapeutic use) |
| 20 | Antidepressant agent |
| 20 | Alzheimer Disease (pathology) |
| 19 | Tremor (physiopathology) |
| 19 | Subthalamic Nucleus |
| 19 | Stem cell |
| 19 | Pramipexole |
| 19 | Placebo |
| 19 | Parkinsonian Disorders (pathology) |
| 19 | Parkinson |
| 19 | Neurons (cytology) |
| 19 | NMDA receptor |
| 19 | Movement Disorders (therapy) |
| 19 | Movement Disorders (etiology) |
| 19 | Mitochondria (metabolism) |
| 19 | Lewy Bodies (pathology) |
| 19 | History, 20th Century |
| 19 | History, 19th Century |
| 19 | Excitability disorder |
| 19 | Deep Brain Stimulation (instrumentation) |
| 19 | Clinical investigation |
| 19 | Autoradiography |
| 19 | Apomorphine (pharmacology) |
| 19 | Apomorphine (administration & dosage) |
| 19 | Antioxidant |
| 18 | Postural hypotension |
| 18 | Phosphorylation |
| 18 | Neuroprotection |
| 18 | Nerve Net (physiopathology) |
| 18 | Mice, Transgenic |
| 18 | Macaca mulatta |
| 18 | Longitudinal Studies |
| 18 | Lipids |
| 18 | Learning |
| 18 | Facial Expression |
| 18 | Dysfunction |
| 18 | Dopaminergic transmission |
| 18 | DNA Mutational Analysis |
| 18 | Cell Death (physiology) |
| 18 | Bromocryptine |
| 18 | Behavior, Animal |
| 18 | Apomorphine (therapeutic use) |
| 18 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology) |
| 17 | Synucleins |
| 17 | Subthalamic Nucleus (metabolism) |
| 17 | Stereotaxic surgery |
| 17 | Signal Transduction |
| 17 | Sex Factors |
| 17 | Risk |
| 17 | Psychomotor Performance (drug effects) |
| 17 | Postural Balance (physiology) |
| 17 | Polymorphism |
| 17 | Piribedil |
| 17 | Parkinsonian Disorders (physiopathology) |
| 17 | Oxidopamine (toxicity) |
| 17 | Norepinephrine |
| 17 | Methodology |
| 17 | Globus Pallidus (surgery) |
| 17 | Genetic Predisposition to Disease (genetics) |
| 17 | Fall |
| 17 | Environment |
| 17 | Cross-Over Studies |
| 17 | Concomitant disease |
| 17 | Cognition Disorders (psychology) |
| 17 | Classification |
| 17 | Cell Count |
| 17 | Catheter Ablation |
| 17 | Biomechanical Phenomena |
| 17 | Bibliographic review |
| 17 | Attention |
| 17 | Attention (physiology) |
| 17 | Ageing |
| 16 | alpha-Synuclein |
| 16 | Thalamus (surgery) |
| 16 | Single photon emission tomography |
| 16 | Primates |
| 16 | Photic Stimulation |
| 16 | Pharmacotherapy |
| 16 | Parkinson Disease, Secondary (metabolism) |
| 16 | Neurotransmitter |
| 16 | Neurosurgical Procedures |
| 16 | Neurons (enzymology) |
| 16 | Neurodegenerative Diseases (physiopathology) |
| 16 | Multivariate Analysis |
